

# Holly M Nguyen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10443824/publications.pdf>

Version: 2024-02-01

30  
papers

2,674  
citations

430874

18  
h-index

454955

30  
g-index

33  
all docs

33  
docs citations

33  
times ranked

3907  
citing authors

#	ARTICLE	IF	CITATIONS
1	Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. <i>Journal of Clinical Investigation</i> , 2010, 120, 2715-2730.	8.2	633
2	Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. <i>Cancer Cell</i> , 2017, 32, 474-489.e6.	16.8	483
3	Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. <i>Journal of Clinical Investigation</i> , 2019, 129, 4492-4505.	8.2	250
4	LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics. <i>Prostate</i> , 2017, 77, 654-671.	2.3	219
5	Prostate cancer reactivates developmental epigenomic programs during metastatic progression. <i>Nature Genetics</i> , 2020, 52, 790-799.	21.4	174
6	A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening. <i>Clinical Cancer Research</i> , 2018, 24, 4332-4345.	7.0	154
7	Ferroptosis Inducers Are a Novel Therapeutic Approach for Advanced Prostate Cancer. <i>Cancer Research</i> , 2021, 81, 1583-1594.	0.9	140
8	November GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models. <i>Prostate</i> , 2018, 78, 1262-1282.	2.3	76
9	Reprogramming of the FOXA1 cisome in treatment-emergent neuroendocrine prostate cancer. <i>Nature Communications</i> , 2021, 12, 1979.	12.8	70
10	Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling. <i>PLoS ONE</i> , 2013, 8, e78881.	2.5	60
11	Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. <i>Nature Communications</i> , 2021, 12, 5775.	12.8	59
12	Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts. <i>European Urology</i> , 2020, 77, 144-155.	1.9	46
13	Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts. <i>Prostate</i> , 2015, 75, 303-313.	2.3	31
14	Circular RNAs add diversity to androgen receptor isoform repertoire in castration-resistant prostate cancer. <i>Oncogene</i> , 2019, 38, 7060-7072.	5.9	31
15	Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1667-1677.	7.0	30
16	High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer. <i>Scientific Reports</i> , 2018, 8, 17239.	3.3	29
17	Establishment and serial passage of cell cultures derived from LuCaP xenografts. <i>Prostate</i> , 2013, 73, 1251-1262.	2.3	27
18	Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer. <i>Prostate</i> , 2016, 76, 325-334.	2.3	25

#	ARTICLE	IF	CITATIONS
19	Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts. <i>Clinical Cancer Research</i> , 2017, 23, 2301-2312.	7.0	20
20	MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer. <i>Scientific Reports</i> , 2021, 11, 13305.	3.3	20
21	RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer. <i>Cancer Research</i> , 2021, 81, 4736-4750.	0.9	18
22	Conversion of Prostate Adenocarcinoma to Small Cell Carcinoma-Like by Reprogramming. <i>Journal of Cellular Physiology</i> , 2016, 231, 2040-2047.	4.1	14
23	A bladder cancer patient-derived xenograft displays aggressive growth dynamics in vivo and in organoid culture. <i>Scientific Reports</i> , 2021, 11, 4609.	3.3	14
24	Antitumor Activity of the IGF-1/IGF-2 Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1059-1069.	4.1	12
25	Response to supraphysiological testosterone is predicted by a distinct androgen receptor cistrome. <i>JCI Insight</i> , 2022, 7, .	5.0	9
26	Yttrium-90-Labeled Anti-Glypican 3 Radioimmunotherapy Halts Tumor Growth in an Orthotopic Xenograft Model of Hepatocellular Carcinoma. <i>Journal of Oncology</i> , 2019, 2019, 1-7.	1.3	8
27	Generation of Prostate Cancer Patient-Derived Xenografts to Investigate Mechanisms of Novel Treatments and Treatment Resistance. <i>Methods in Molecular Biology</i> , 2018, 1786, 1-27.	0.9	7
28	Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature. <i>PLoS ONE</i> , 2021, 16, e0245602.	2.5	5
29	Methodology to Investigate Androgen-Sensitive and Castration-Resistant Human Prostate Cancer Xenografts in Preclinical Setting. <i>Methods in Molecular Biology</i> , 2011, 776, 295-312.	0.9	3
30	Caring for the Animal Caregiver Occupational Health, Human-Animal Bond and Compassion Fatigue. <i>Frontiers in Veterinary Science</i> , 2021, 8, 731003.	2.2	1